Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03997968
Title A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Cyteir Therapeutics, Inc.

mantle cell lymphoma

ovarian cancer

diffuse large B-cell lymphoma


non-Hodgkin lymphoma

breast cancer

chronic lymphocytic leukemia

head and neck squamous cell carcinoma

pancreatic cancer

multiple myeloma

triple-receptor negative breast cancer



Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.